580 related articles for article (PubMed ID: 9605165)
21. Kinetic analysis of the interactions between vaccinia virus complement control protein and human complement proteins C3b and C4b.
Bernet J; Mullick J; Panse Y; Parab PB; Sahu A
J Virol; 2004 Sep; 78(17):9446-57. PubMed ID: 15308738
[TBL] [Abstract][Full Text] [Related]
22. Phosphorylation of C3 by a casein kinase released from activated human platelets increases opsonization of immune complexes and binding to complement receptor type 1.
Nilsson-Ekdahl K; Nilsson B
Eur J Immunol; 2001 Apr; 31(4):1047-54. PubMed ID: 11298329
[TBL] [Abstract][Full Text] [Related]
23. Cell-surface regulation of the human alternative pathway of complement. Sheep but not rabbit erythrocytes express factor I-dependent cofactor activity.
Ezzell JL; Parker CJ
Scand J Immunol; 1992 Jul; 36(1):79-87. PubMed ID: 1535452
[TBL] [Abstract][Full Text] [Related]
24. Residual hemolytic and proteolytic activity expressed by Bb after decay-dissociation of C3b,Bb.
Fishelson Z; Müller-Eberhard HJ
J Immunol; 1984 Mar; 132(3):1425-9. PubMed ID: 6229580
[TBL] [Abstract][Full Text] [Related]
25. Functional characterization of the complement control protein homolog of herpesvirus saimiri: ARG-118 is critical for factor I cofactor activities.
Singh AK; Mullick J; Bernet J; Sahu A
J Biol Chem; 2006 Aug; 281(32):23119-28. PubMed ID: 16760474
[TBL] [Abstract][Full Text] [Related]
26. Functional characterization of soluble and membrane-bound forms of vaccinia virus complement control protein (VCP).
Rosengard AM; Alonso LC; Korb LC; Baldwin WM; Sanfilippo F; Turka LA; Ahearn JM
Mol Immunol; 1999 Jul; 36(10):685-97. PubMed ID: 10509819
[TBL] [Abstract][Full Text] [Related]
27. Complement C3b interactions studied with surface plasmon resonance technique.
Jokiranta TS; Westin J; Nilsson UR; Nilsson B; Hellwage J; Löfås S; Gordon DL; Ekdahl KN; Meri S
Int Immunopharmacol; 2001 Mar; 1(3):495-506. PubMed ID: 11367533
[TBL] [Abstract][Full Text] [Related]
28. Epstein-Barr virus regulates activation and processing of the third component of complement.
Mold C; Bradt BM; Nemerow GR; Cooper NR
J Exp Med; 1988 Sep; 168(3):949-69. PubMed ID: 2844953
[TBL] [Abstract][Full Text] [Related]
29. Identification of complement regulatory domains in vaccinia virus complement control protein.
Mullick J; Bernet J; Panse Y; Hallihosur S; Singh AK; Sahu A
J Virol; 2005 Oct; 79(19):12382-93. PubMed ID: 16160165
[TBL] [Abstract][Full Text] [Related]
30. A discontinuous factor H binding site in the third component of complement as delineated by synthetic peptides.
Lambris JD; Avila D; Becherer JD; Müller-Eberhard HJ
J Biol Chem; 1988 Aug; 263(24):12147-50. PubMed ID: 2969896
[TBL] [Abstract][Full Text] [Related]
31. Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis.
Klickstein LB; Bartow TJ; Miletic V; Rabson LD; Smith JA; Fearon DT
J Exp Med; 1988 Nov; 168(5):1699-717. PubMed ID: 2972794
[TBL] [Abstract][Full Text] [Related]
32. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane.
Fearon DT
Proc Natl Acad Sci U S A; 1979 Nov; 76(11):5867-71. PubMed ID: 293688
[TBL] [Abstract][Full Text] [Related]
33. Human factor H-related protein 5 has cofactor activity, inhibits C3 convertase activity, binds heparin and C-reactive protein, and associates with lipoprotein.
McRae JL; Duthy TG; Griggs KM; Ormsby RJ; Cowan PJ; Cromer BA; McKinstry WJ; Parker MW; Murphy BF; Gordon DL
J Immunol; 2005 May; 174(10):6250-6. PubMed ID: 15879123
[TBL] [Abstract][Full Text] [Related]
34. Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes.
Medof ME; Iida K; Mold C; Nussenzweig V
J Exp Med; 1982 Dec; 156(6):1739-54. PubMed ID: 7175439
[TBL] [Abstract][Full Text] [Related]
35. Formation of high-affinity C5 convertases of the alternative pathway of complement.
Rawal N; Pangburn M
J Immunol; 2001 Feb; 166(4):2635-42. PubMed ID: 11160326
[TBL] [Abstract][Full Text] [Related]
36. Complement alternative pathway activation and control on membranes of human lymphoid B cell lines.
Caudwell V; Porteu F; Calender A; Pangburn MK; Halbwachs-Mecarelli L
Eur J Immunol; 1990 Dec; 20(12):2643-50. PubMed ID: 1702720
[TBL] [Abstract][Full Text] [Related]
37. Mechanism of resistance to lysis by the alternative complement pathway in Trypanosoma cruzi trypomastigotes: effect of specific monoclonal antibody.
Schenkman S; Güther ML; Yoshida N
J Immunol; 1986 Sep; 137(5):1623-8. PubMed ID: 2943798
[TBL] [Abstract][Full Text] [Related]
38. The interaction of C3b bound to pneumococci with factor H (beta 1H globulin), factor I (C3b/C4b inactivator), and properdin factor B of the human complement system.
Brown EJ; Joiner KA; Gaither TA; Hammer CH; Frank MM
J Immunol; 1983 Jul; 131(1):409-15. PubMed ID: 6223077
[TBL] [Abstract][Full Text] [Related]
39. Preimplantation embryos cooperate with oviductal cells to produce embryotrophic inactivated complement-3b.
Tse PK; Lee YL; Chow WN; Luk JM; Lee KF; Yeung WS
Endocrinology; 2008 Mar; 149(3):1268-76. PubMed ID: 18039777
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of the alternative C3 convertase and classical C5 convertase of complement by group A streptococcal M protein.
Hong K; Kinoshita T; Takeda J; Kozono H; Pramoonjago P; Kim YU; Inoue K
Infect Immun; 1990 Aug; 58(8):2535-41. PubMed ID: 2142480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
